Download here

ImmuPharma PLC (LON:IMM) CEO Dimitri Dimitriou and Chairman Tim McCarthy discuss with Proactive Investors the top-line results from their phase III trial of the drug Lupuzor™. The data revealed Lupuzor™ was more effective than the placebo (52.5% versus 44.6%) however because the response rate for those taking the non-active medication plus the “standard of care”…

Download here

Download here

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces the results of its pivotal Phase III trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus. Key highlights: Lupuzor™ demonstrated a superior response rate over placebo* (52.5% vs 44.6% “responders”**) in the primary analysis on the Full Analysis Set of…

ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, is pleased to announce that it has with immediate effect appointed Bryan, Garnier & Co. Limited as its joint corporate broker to act alongside Northland Capital Partners who remain the Company’s Nominated Adviser and joint corporate broker. Tim McCarthy, Chairman of Immupharma, commented: “We…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company announces that it has been informed by Simbec-Orion, the contract research organisation conducting our Lupuzor™ pivotal Phase III trial study, that ‘database lock’ is expected on 6 April 2018 with top line results announced by mid-April 2018. Lupuzor™ is the Company’s lead programme for the…

ImmuPharma PLC (LSE: IMM), specialist drug discovery and development company, is pleased to announce that Tim McCarthy, Chairman, will be presenting at an investor evening hosted by Turner Pope Investments (TPI) Ltd. TPI acted as agent in the recent successful £10 million fundraise by ImmuPharma. The event will be held on Monday 26th February 2018…

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company, announces that on 8 February 2018 it received notification that Alto Invest no longer holds a notifiable interest in the Company. This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, has received notification that Lanstead Capital LP (“Lanstead”) has confirmed an increase in its holding in ImmuPharma. Lanstead now holds 6,985,893 Ordinary shares of 10p each in the Com-pany, representing 5.01% of ImmuPharma’s issued share capital of 139,467,430 Ordinary shares with voting rights. This announcement…